17 research outputs found
Fish colonization of a newly deployed vessel-reef off southeast Florida: preliminary results [abstract]
Avaliação do Desempenho Reprodutivo de Novilhas de Corte Primíparas aos Dois Anos de Idade
Características da lactação de vacas Hereford criadas em um sistema de produção extensivo na região da campanha do Rio Grande do Sul
Cannibalism and kin recognition in Delena cancerides (Araneae: Sparassidae), a social huntsman spider
Natal dispersal and breeding dispersal of a subsocial spitting spider (Scytodes pallida) (Araneae: Scytodidae), from Singapore
10.1111/j.1469-7998.2005.00028.xJournal of Zoology2682121-126JOZO
Migrants in Neotropical bird communities: an assessment of the breeding currency hypothesis
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
BACKGROUND: Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19) under the presumption that such plasma contains potentially therapeutic antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be passively transferred to the plasma recipient. Whether convalescent plasma with high antibody levels rather than low antibody levels is associated with a lower risk of death is unknown. METHODS: In a retrospective study based on a U.S. national registry, we determined the anti-SARS-CoV-2 IgG antibody levels in convalescent plasma used to treat hospitalized adults with Covid-19. The primary outcome was death within 30 days after plasma transfusion. Patients who were enrolled through July 4, 2020, and for whom data on anti-SARS-CoV-2 antibody levels in plasma transfusions and on 30-day mortality were available were included in the analysis. RESULTS: Of the 3082 patients included in this analysis, death within 30 days after plasma transfusion occurred in 115 of 515 patients (22.3%) in the high-titer group, 549 of 2006 patients (27.4%) in the medium-titer group, and 166 of 561 patients (29.6%) in the low-titer group. The association of anti-SARS-CoV-2 antibody levels with the risk of death from Covid-19 was moderated by mechanical ventilation status. A lower risk of death within 30 days in the high-titer group than in the low-titer group was observed among patients who had not received mechanical ventilation before transfusion (relative risk, 0.66; 95% confidence interval [CI], 0.48 to 0.91), and no effect on the risk of death was observed among patients who had received mechanical ventilation (relative risk, 1.02; 95% CI, 0.78 to 1.32). CONCLUSIONS: Among patients hospitalized with Covid-19 who were not receiving mechanical ventilation, transfusion of plasma with higher anti-SARS-CoV-2 IgG antibody levels was associated with a lower risk of death than transfusion of plasma with lower antibody levels. (Funded by the Department of Health and Human Services and others; ClinicalTrials.gov number, NCT04338360.)